Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib and Nivolumab in Pretreated Advanced NSCLC
NCT04046614Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in lung adenocarcinoma, sponsored by AIO-Studien. Primary endpoints: Safety and tolerability as determined by frequency and severity of adverse events at 47 months and Progression-Free Survival at 6 months. Started May 2018; status: completed.
02
Drugs
nintedanib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT04046614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046614.